Research
Hormonal
Long-acting amylin analogues have beneficial effects on body weight in obesity.
Long-acting amylin analogues may be considered as a treatment option for obesity.
StrongSupportsmedium confidence
Both preclinical and early-stage clinical studies investigating long-acting amylin receptor analogues demonstrate beneficial effects on body weight in obesity.
Why this rating
Based on the mention of preclinical and early-stage clinical studies.
Source
Long-acting amylin analogues for the management of obesity
David S. Mathiesen et al. · Current Opinion in Endocrinology Diabetes and Obesity · 2022
DOI 10.1097/med.0000000000000716
reviewCited 37×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →